SIBO: Diagnostic Testing and First-Line Treatment
For suspected SIBO, prioritize hydrogen AND methane breath testing (using glucose or lactulose) over empirical antibiotics to improve diagnostic accuracy and antibiotic stewardship, then treat confirmed cases with rifaximin 550 mg twice daily for 1-2 weeks, which achieves 60-80% efficacy. 1
Diagnostic Approach
Testing Strategy
The most recent 2025 British Society of Gastroenterology guidance represents a significant shift from previous empirical treatment approaches. Testing rather than empirical treatment should be used whenever possible to establish the diagnosis, particularly given that multiple overlapping conditions often coexist and lack of antibiotic response may reflect resistant organisms, absence of SIBO, or concurrent disorders 1.
Recommended Diagnostic Tests (in order of preference):
1. Combined Hydrogen and Methane Breath Testing (Preferred)
- Use glucose OR lactulose as substrate
- Methane analysis combined with hydrogen significantly increases diagnostic accuracy compared to hydrogen alone 1
- Non-invasive, accessible, and lower cost
- Limitations: Not always accurate; false positives and negatives occur
- When clearly positive, confirms SIBO presence 1
2. Qualitative Small Bowel Aspiration (Alternative)
- Much easier to perform than quantitative culture
- Requires pre-arrangement with local microbiology for appropriate processing and reporting
- Technique via upper endoscopy 1:
- Avoid aspirating on intubation
- Flush 100 mL sterile saline into duodenum
- Flush channel with 10 mL air
- Turn down suction
- Wait few seconds
- Aspirate ≥10 mL into sterile trap
- Positive aspirates grow colonic bacteria
3. Quantitative Small Bowel Aspiration
- Traditional gold standard (>10⁵ CFU/mL)
- Time-consuming and invasive
- Less practical for routine clinical use 1, 2
When Empirical Treatment May Be Considered
Only if testing unavailable or inaccessible 1. However, this approach is no longer recommended as first-line given antibiotic stewardship concerns.
First-Line Treatment
Primary Antibiotic Therapy
Rifaximin 550 mg twice daily for 1-2 weeks 1
- Most investigated treatment with 60-80% efficacy in proven SIBO
- Non-absorbed from GI tract, reducing systemic resistance risk
- Preferred over absorbed antibiotics for safety profile
Alternative Equally Effective Antibiotics
When rifaximin unavailable or cost-prohibitive 1:
- Doxycycline
- Ciprofloxacin
- Amoxicillin-clavulanic acid
- Cefoxitin
Metronidazole is less effective and should be avoided 1
Treatment Duration Strategy
Single reversible cause (e.g., chemotherapy-induced immunosuppression):
- One course of antibiotics typically sufficient 1
Recurrent SIBO:
- Low-dose long-term antibiotics
- Cyclical antibiotics
- Recurrent short courses 1
Critical Clinical Pearls
Common Diagnostic Pitfalls
Low faecal elastase (<500 μg/g) may indicate SIBO, not just pancreatic insufficiency, untreated coeliac disease, or watery stool 1
PERT intolerance often indicates underlying SIBO—once SIBO eradicated, PERT becomes tolerated 1
Breath testing limitations: Sensitivity ranges 20-93% for glucose, 31-68% for lactulose; specificity varies widely 3
High-Risk Populations Requiring Testing
- Post-cancer treatment patients (very common occurrence) 1
- Stricturing or fistulizing Crohn's disease (up to 30% prevalence) 3
- Loss of ileocecal valve 3
- Chronic watery diarrhea with malnutrition/weight loss
- Systemic diseases causing small bowel dysmotility 4
Antibiotic Stewardship Considerations
Non-absorbed antibiotics (rifaximin) are preferable to systemically absorbed options to minimize resistance development 1. The 2025 BSG guidance explicitly prioritizes testing over empirical treatment to support appropriate antibiotic use 1.
Adjunctive Therapies
While antibiotics remain the cornerstone, consider:
- Probiotics for symptom management 5
- Low FODMAP diet to complement antibiotic therapy 6
- Prokinetic agents in patients with underlying dysmotility 7
These should supplement, not replace, antibiotic eradication therapy.